For example, CXCL2 promotes neutrophil recruitment and inflammatory responses via the CXCR2 axis, and inhibiting CXCR2 can alleviate myeloid inflammation and reverse treatment resistance in prostate cancer [183,184]. Here, CXCR2 is linked to prostate carcinoma.